AlphaStocks
2.0
Avoid

Enovis CORP (ENOV)

As of Sep 20, 2026, Enovis CORP (ENOV) scores 2.0/10 on AlphaStocks' five-model composite, #164 of 168 Health Care stocks. At $18, ENOV trades 87% above its model fair value of $9.64.

Health Care / Health Care Equipment

S&P SmallCap 600

$18.04

Scores poorly across most models. Proceed with caution.

Avoid

Score based on 4 of 5 models — moderate confidence

Data as of Sep 20, 2026

#164out of 168 in Health Care

Is Enovis CORP a Good Investment in 2026?

Enovis CORP (ENOV) scores 2.0 out of 10 on AlphaStocks' composite model, earning a Avoid rating. The Piotroski model is the most favorable, rating Enovis CORP as Neutral. However, the Greenblatt Magic Formula model rates it Caution — Earnings yield -41.1% · ROC -101%. Enovis CORP currently trades 87% above its estimated fair value of $9.64. Enovis CORP ranks #164 out of 168 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

ROE-67.5Market Cap1B

Estimated Fair Value

$9.6487% above

Trading above estimated fair value — the market may be pricing in future growth.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Neutral

4/9

Buffett

Caution

Business quality & competitive moat

Graham

Neutral

Price vs intrinsic value

Lynch

Neutral

Growth rate vs price (PEG)

Greenblatt

Caution

Earnings yield -41.1% · ROC -101%

Frequently Asked Questions

Is Enovis CORP (ENOV) a good investment?
As of Sep 20, 2026, Enovis CORP (ENOV) scores 2.0/10 on AlphaStocks' five-model composite, #164 of 168 Health Care stocks. At $18, ENOV trades 87% above its model fair value of $9.64. That score is below average, suggesting caution.
What is Enovis CORP's Piotroski F-Score?
Enovis CORP's Piotroski F-Score status is Neutral. The raw score is 4/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is ENOV overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $9.64, ENOV appears overvalued. The stock currently trades 87% above its estimated fair value. Trading above estimated fair value — the market may be pricing in future growth.
How does ENOV compare to other Health Care stocks?
Enovis CORP ranks #164 out of 168 stocks in the Health Care sector, placing it in the top 98% of its sector by composite score. There are higher-ranked alternatives in this sector worth exploring.
What do investment models say about ENOV?
AlphaStocks evaluates ENOV using five proven investment models. Piotroski: Neutral; Buffett: Caution; Graham: Neutral; Lynch: Neutral; Greenblatt Magic Formula: Caution. These models are combined into a single composite score of 2.0/10.

Similar Stocks

INSPUFPTBDX

Compare ENOV with

ENOV vs INSPENOV vs UFPTBDX vs ENOV

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer